Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Current Hematologic Malignancy Reports
Ryuzo Ohno

Abstract

In the pre-imatinib era, the treatment outcome of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) was dismal. Complete remission was generally achieved only in about 50% to 60% of patients, and allogeneic hematopoietic stem cell transplantation (allo-HSCT), when feasible in younger patients, was virtually the sole curative modality. Imatinib has changed the situation dramatically, however, in combination with conventional chemotherapy or with corticosteroid alone, producing about 95% complete remission and thus increasing the number of patients undergoing allo-HSCT. Currently, the overall survival of patients who have undergone allo-HSCT exceeds 50%, and a considerable proportion of patients for whom allo-HSCT is not feasible are predictably curable. The next question is how to prevent relapse, which is observed not only in more than half of patients for whom allo-HSCT is not feasible but also in a considerable number of patients after allo-HSCT. Thus, improvement of postremission therapy is crucial. Whether intensive chemotherapy with currently available cytotoxic drugs contributes to the prevention of relapse is questionable, because intensive chemotherapy alone in the pre-imatinib era ...Continue Reading

References

Apr 6, 2000·The New England Journal of Medicine·M AricòG Masera
Sep 20, 2002·Blood·Hervé DombretUNKNOWN Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group)
Nov 24, 2005·Hematology·Oliver G Ottmann, Barbara Wassmann
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masamitsu YanadaUNKNOWN Japan Adult Leukemia Study Group
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
Jul 20, 2006·International Journal of Clinical Oncology·Ryuzo Ohno
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Dec 19, 2008·International Journal of Hematology·Masamitsu YanadaTomoki Naoe
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirk R SchultzBruce Camitta
Jan 15, 2010·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Markus Lindauer, Andreas Hochhaus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Asher Chanan-KhanPaul G Richardson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
James R BerensonAmerican Society of Clinical Oncology Bisphosphonates Expert Panel
© 2021 Meta ULC. All rights reserved